Recent research indicates that semaglutide, an effective drug for managing obesity and diabetes, could be produced for as little as $3 per month. This significant reduction in cost could potentially revolutionise access to treatment for millions living in lower-income countries, particularly as patents begin to expire. The findings come at a crucial time as global obesity rates continue to rise alarmingly.
A Game Changer for Global Health
Semaglutide, marketed under the brand names Wegovy for obesity and Ozempic for diabetes, was designated as an essential medicine by the World Health Organization (WHO) in September 2022. Despite its recognition, access remains a pressing issue due to its high price tag, especially for the world’s most vulnerable populations. The new analysis suggests that mass production of the injectable form of the drug could drastically lower costs, paving the way for broader accessibility.
Dr Andrew Hill from Liverpool University’s pharmacology department, one of the study’s authors, highlighted the potential for global access, stating, “These low prices open the door to worldwide access to an essential medicine.” Such affordability could enable treatment for the 1.1 billion individuals globally living with obesity, a number that is growing rapidly, especially in lower-income nations as diets modernise and lifestyles become more sedentary.
Patent Expirations and New Opportunities
The research highlights that core patents for semaglutide are set to expire in ten countries, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, as early as March 21, 2026. This development is expected to usher in generic competition, lowering prices further and expanding availability. Additionally, the study identified around 150 countries where patents were not filed, particularly across Africa, which hosts a significant proportion of those suffering from obesity and type 2 diabetes.
Prof François Venter from Witwatersrand University in Johannesburg remarked on the precedent set by other essential medicines, noting, “Drugs to treat HIV, TB, malaria, and hepatitis are available in low- and middle-income countries for prices close to the cost of production, saving millions of lives.” He expressed optimism that a similar success story could unfold for semaglutide.
Addressing Underlying Issues
While the prospect of cheaper semaglutide is promising, experts caution that it does not address the root causes of obesity, such as food insecurity and socio-economic disparities. Dr Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, emphasised the need for health systems to integrate these treatments responsibly within broader strategies for managing obesity and diabetes.
Chandiwana pointed out that approximately 27% of adults globally meet the criteria for medications like semaglutide, with many residing in low- and middle-income nations where access is severely limited. The integration of affordable treatments into healthcare systems must be accompanied by comprehensive policies that tackle the structural drivers of obesity.
The Growing Diabetes Epidemic
The rise in diabetes cases is particularly concerning, with numbers increasing from 200 million in 1990 to 830 million by 2022. The steepest increases have been observed in low- and middle-income countries, where healthcare resources are often scarce. The implications of untreated diabetes are severe, as it is linked to various health complications, including heart disease, stroke, and cancer.
Semaglutide was first approved by US regulators in 2017, yet it currently costs around $200 per month in the United States and £120 in the UK. With patents still in place in these markets for the next five years, the timing of this study is critical, as it raises awareness about the potential for more affordable treatment options.
Why it Matters
The findings from this research underscore a pivotal moment in global health, offering hope for millions suffering from obesity and diabetes in resource-limited settings. By making semaglutide more accessible, there is an opportunity not only to improve individual health outcomes but also to alleviate the broader public health crisis posed by obesity and diabetes. As we strive for equitable healthcare, addressing both the affordability of essential medicines and the systemic issues driving these health conditions will be crucial in creating a healthier, more sustainable future for all.
